1. Home
  2. > Healthcare
  3. > Health Services Market Trends
Antibody-Mediated Rejection - Epidemiology Forecast - 2032

Antibody-Mediated Rejection - Epidemiology Forecast - 2032

  • August 2022
  • 78 pages
  • ID: 6316468
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

" Antibody-Mediated Rejection (AMR) - Epidemiology Forecast-2032" report delivers an in-depth understanding of the Antibody-Mediated Rejection, historical and forecasted epidemiology as well as the Antibody-Mediated Rejection trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2019-2032

Antibody-Mediated Rejection (AMR) Understanding
The’s Antibody-Mediated Rejection market report gives a thorough understanding of Antibody-Mediated Rejection. Antibody?mediated rejection (AMR) is a significant complication following organ transplantation that contributes to short? and long?term injury in transplant recipients. Despite desensitization protocols, up to one?third of highly sensitized recipients may develop acute AMR following transplantation. AMR is also of significant concern in non-sensitized individuals, as de novo DSAs can develop early or late after transplantation.
The phenotype of AMR ranges from hyperacute rejection, acute AMR, and chronic AMR. AMR diagnosis depends on typical histological lesions, C4d staining, and serum DSA detection. C4d, a protein from the classical complement activation cascade that remains attached to the site of complement activation, is regarded as a diagnostic marker for AMR. The introduction of C4d as a marker of AMR aroused an ever-increasing interest in recognizing mechanisms of allograft rejection. AMR episodes occurring at different periods seem to be different clinical sub-entities. Early AMR is usually correlated with sensitization, pre-existing alloantibodies, and rapid graft dysfunction and is usually easy to be controlled; while late AMR is mostly correlated with withdrawal or reduction of immunosuppressants and noncompliance with immunosuppressive therapy, whereas late AMR has little response to antirejection strategies and thus correlate with poor graft outcomes.
The diagnosis of AMR—as defined by the modified Banff 97 and recently revised in the Banff 2019 classification—requires three cardinal features, including (a) functional evidence of allograft dysfunction, (b) morphological evidence of acute tissue injury, and evidence of Ab-dependent activation of the classical pathway of the complement system (i.e., C4d deposition in the peritubular capillaries), and detection of circulating DRSA. This report covers five major organ transplants where AMR is defined, namely Kidney, Lung, Liver, Heart, and Pancreas.

Antibody-Mediated Rejection (AMR) Epidemiology
The epidemiology section provides insights about the historical and current Antibody-Mediated Rejection patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
The disease epidemiology covered in the report provides a historical as well as forecasted Antibody-Mediated Rejection epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
In the year 2021, the total cases of Antibody-Mediated Rejection were 5,102 in the 7MM which are expected to grow during the study period, i.e., 2019–2032.
The disease epidemiology covered in the report provides historical as well as forecasted Antibody-Mediated Rejection epidemiology ,segmented as Transplant Incident cases and Total cases of Antibody-Mediated Rejection in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Antibody-Mediated Rejection Epidemiology
The epidemiology segment also provides the Antibody-Mediated Rejection epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

KOL- Views
To keep up with the current Antibody-Mediated Rejection patient pool and forecasted trend, we take KOLs and SMEs ’ opinions working in the Antibody-Mediated Rejection domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.

Scope of the Report
• The report covers the descriptive overview of Antibody-Mediated Rejection, explaining their causes, symptoms, pathophysiology, and genetic basis.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Antibody-Mediated Rejection.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The disease epidemiology covered in the report provides historical as well as forecasted Antibody-Mediated Rejection epidemiology [segmented as Transplant incident cases (by organs) and Antibody-Mediated Rejection cases (by organ transplant)] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Antibody-Mediated Rejection R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Antibody-Mediated Rejection.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Antibody-Mediated Rejection (AMR) Report Key Strengths
• 11 Years Forecast
• 7MM Coverage
• Antibody-Mediated Rejection Epidemiology Segmentation

Key Questions

Epidemiology Insights:
• What are the disease risk, burden, and regional/ethnic differences of Antibody-Mediated Rejection?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Antibody-Mediated Rejection patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Antibody-Mediated Rejection in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about Antibody-Mediated Rejection?
• Out of all 7MM countries, which country would have the highest incident population of Antibody-Mediated Rejection during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

Reasons to buy
• The report will help in developing business strategies by understanding trends shaping and driving the Antibody-Mediated Rejection Disease market
• To understand the future market competition in the Antibody-Mediated Rejection Disease market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Antibody-Mediated Rejection Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Antibody-Mediated Rejection Disease market
• To understand the future market competition in the Antibody-Mediated Rejection Disease market

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Autism Spectrum Disorder Epidemiology Analysis and Forecast, 2021-2031

  • $ 3995
  • September 2022
  • 30 pages

Autism Spectrum Disorder Epidemiology Analysis and Forecast, 2021-2031 Summary ASD is one of the most common developmental disorders worldwide.The condition affects 4% of children worldwide, making the ...

  • United States
  • World
  • Mental Health
  • Epidemiology
  • Industry analysis
  • Prescription Drug Sales
  • Breast Screening Coverage

ref:plp2022

Reportlinker.com © Copyright 2023. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on